Taiwan Frederic Kuo, founder and CEO of Fethiann, established the company in 2017 within Taiwan’s Hsinchu Science Park. With a PhD background and extensive experience in new drug development, Frederick has positioned Fethiann as Taiwan’s sole specialist in natural phytochemical active pharmaceuticals. The company’s unique business model integrates Active Phytochemicals Ingredient…
USA The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial after patient death; Courts half another attempt to challenge the IRA’s negation program; Takeda scoops up former Lilly exec to…
Denmark Michael Kocher, Chief Executive Officer of Xellia, brings over 15 years of pharmaceutical industry experience to his leadership role at the Danish API manufacturer. Under his leadership since October 2023, the company has undertaken a comprehensive strategic realignment, divesting its US operations while refocusing on its core competencies in fermentation-based…
Colombia Clara Isabel Rodríguez, Executive Director of the Colombian Association of the Pharmaceutical Industry (ASCIF), shares her journey from public sector leadership to industry advocacy. With deep experience in health regulation and public administration, Rodríguez reflects on Colombia’s pharma landscape, the challenges of ongoing health reform, and why local manufacturing is…
Switzerland In a health and wellness landscape crowded with disputable claims and flash-in-thepan trends, A.Vogel stands out for its quiet consistency and scientific conviction. Over the past five years, the Swiss-based natural health company has doubled down on quality, transparency, and long-term vision; from scaling up GMP-certified production and running clinical…
Switzerland Marking 160 years of uninterrupted evolution, Max Zeller stands at the intersection of tradition and modernity in plant-based healthcare. CEO Georg Boonen reflects on the company’s continued role in shaping evidence-based phytotherapy, from pioneering prescription-grade herbal medicines in Switzerland to launching the Zeller Plus line of preventive supplements. With a…
China A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled research deal with CSPC Pharmaceuticals, and the FDA blocks clinical trials that export American’s cells to China. Sciwind’s GLP‑1 data…
Brazil A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera after a failed merger attempt, and Quantoom, Univercells and Fiocruz’s RNA-based vaccine production collaboration. MediPharm Labs Enters Landmark Commercial…
Europe Jazz Pharmaceuticals is about to open a new chapter in its history. As long-standing CEO and co-founder Bruce Cozadd prepares to step down for retirement, the neuroscience and oncology-focused company begins its search for a new leader and gets ready to commercialize recently FDA-approved HER2-targeted bispecific antibody, Ziihera. End…
China The R&D-Based Pharmaceutical Association Committee (RDPAC) under the China Association of Enterprises with Foreign Investment (CAEFI) represents 46 multinational pharmaceutical companies with a strong R&D presence in China. Managing Director Renaud Gabay discusses how member companies are leveraging synchronized approvals to accelerate access; the evolution of China’s regulatory framework that…
China A roundup of some of the biggest China pharma industry stories, including the progress of the US Biosecure Act targeting Chinese biotechs; Innovent’s obesity and type 2 diabetes contender’s positive phase III trial results; the strategic partnership between Sino Biological and BioGeometry; CSL’s sale of its China-based plasma collection operations…
China A roundup of top stories from China’s pharma industry, including BeiGene’s new US R&D and manufacturing facility; Merck’s purchase of investigational B-cell depletion therapy from Curon Biopharma, and the Chinese approval of AstraZeneca and Daiichi Sankyo’s gastric cancer therapy. China’s BeiGene opens new clinical R&D and biologics manufacturing facility…
See our Cookie Privacy Policy Here
